Beatrice Bacchi

Dr. Beatrice Bacchi


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AAAlessia Argirò
Alessia Argirò
MZmattia zampieri
mattia zampieri
MBMartina Berteotti
Martina Berteotti
AMAlberto Marchi
Alberto Marchi
LTLuigi Tassetti
Luigi Tassetti
Iacopo OlivottoIacopo Olivotto
Iacopo Olivotto
Hypertrophic cardiomyopathy (HCM) is a common myocardial disease characterized by otherwise unexplained left ventricular hypertrophy. The main cause of disabling symptoms in patients with HCM is left ventricular outflow tract (LVOT) obstruction. This phenomenon is multifactorial, determined both by anatomical and functional abnormalities: myocardial hypercontractility is believed to represent one of its major determinants. The anatomical anomalies are targeted by surgical interventions, whereas attenuating hypercontractility is the objective of old and new drugs including the novel class of allosteric myosin inhibitors. This review summarizes the current treatment modalities and discusses the emerging therapeutical opportunities focusing on the recently developed cardiac myosin ATPase inhibitors Mavacamten and CK-274. Novel surgical and interventional approaches are also discussed.

ADAleksander Dokollari
Aleksander Dokollari
GTGianluca Torregrossa
Gianluca Torregrossa
GBGianluigi Bisleri
Gianluigi Bisleri
AHAli Fatehi Hassanabad
Ali Fatehi Hassanabad
MSMichel Pompeu Sa
Michel Pompeu Sa
Massimo BonacchiMassimo Bonacchi
Massimo Bonacchi
Objective: The goal of this manuscript is to compare clinical and echocardiographic outcomes of patients undergoing aortic valve replacement (AVR) with Perceval sutureless bioprosthesis (SU-AVR) and sutured bioprosthesis (SB). Methods: Following the PRISMA statement, data were extracted from studies published after August 2022 and found in PubMed/MEDLINE, EMBASE, CENTRAL/CCTR, ClinicalTrials.gov, SciELO, LILACS, and Google Scholar. The primary outcome of interest was post-procedural permanent pacemaker implantation, and the secondary outcomes were new left bundle branch block (LBBB), moderate/severe paravalvular leak (PVL), valve dislocation (pop-out), need for a second transcatheter heart valve, 30-day mortality, stroke, and echocardiographic outcomes. Results: Twenty-one studies were included in the analysis. When SU-AVR was compared to other SB, mortality ranged from 0 to 6.4% for Perceval and 0 to 5.9% for SB. Incidence of PVL (Perceval 1–19.4% vs. SB 0–1%), PPI (Perceval 2–10.7% vs. SB 1.8–8.5%), and MI (Perceval 0–7.8% vs. SB 0–4.3%) were comparable. In addition, the stroke rate was lower in the SU-AVR group when compared to SB (Perceval 0–3.7% vs. SB 1.8–7.3%). In patients with a bicuspid aortic valve, the mortality rate was 0–4% and PVL incidence was 0–2.3%. Long-term survival ranged between 96.7 and 98.6%. Valve cost analysis was lower for the Perceval valve and higher for sutured bioprosthesis. Conclusions: Compared to SB valves, Perceval bioprosthesis has proved to be a reliable prosthesis for surgical aortic valve replacement due to its non-inferior hemodynamics, implantation speed, reduced cardiopulmonary bypass time, reduced aortic cross-clamp time, and shorter length of stay.

10 November 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Beatrice BacchiBeatrice Bacchi
Beatrice Bacchi
KDKendra Derry
Kendra Derry
TVTasnim Vira
Tasnim Vira
SASami Alnasser
Sami Alnasser
PMPaola Keese Montanhesi
Paola Keese Montanhesi
GBGianluigi Bisleri
Gianluigi Bisleri
Transesophageal echocardiography (TEE) has emerged as the pivotal imaging modality in transcatheter mitral valve replacement (TMVR), bridging the gap between anatomical complexity and procedural precision. Unlike any other tool, TEE accompanies the patient journey across all stages of TMVR, from patient assessment and device selection to intraprocedural guidance and post-implant surveillance, providing real-time insights into valve anatomy, hemodynamics, and complications. This review consolidates the most recent consensus statements, quantitative thresholds, and device-specific considerations, while also highlighting evolving technologies. By outlining best practices for integrating TEE within multimodality workflows and the Heart Team paradigm, this article offers clinicians a comprehensive and practice-oriented roadmap for optimizing TMVR outcomes.

Verified
Journal Article
Open access
PDF file
FCFrancesco Cabrucci
Francesco Cabrucci
Serge SicouriSerge Sicouri
Serge Sicouri
Massimo BaudoMassimo Baudo
Massimo Baudo
Dimitrios E. MagouliotisDimitrios E. Magouliotis
Dimitrios E. Magouliotis
YYYoshiyuki Yamashita
Yoshiyuki Yamashita
BRBasel Ramlawi
Basel Ramlawi
Surgical Aortic Valve Replacement (SAVR) is still one of the pillars of cardiac surgery practice, and its role is evolving into a more complex operation. The competition with structural valve therapies and the urgent demand for less invasive solutions have unleashed surgeons’ creativity in adapting to these new challenges. All the possible ways to surgically replace the aortic valve are analyzed in this review. Surgical techniques, advantages and disadvantages, and key differences are listed, helping surgeons navigate the available options. Sternotomy SAVR is the benchmark, but that is becoming obsolete and, in some cases, no longer performed for teaching purposes. Mini sternotomy is the easiest way to achieve minimal invasiveness in all anatomic situations, while right anterior thoracotomy is an elegant solution mastered by fewer surgeons. Endoscopic and robotic-assisted techniques are shaping the future of SAVR, yet they still lack wide adoption. The choice of approach is mainly dictated by the anatomic features of the patient and the surgeon’s skills. A flow diagram to overcome the learning curve and advance toward more complex surgery is provided here. Mastering as many techniques as possible is paramount when offering a patient-tailored approach and performing a safe and less invasive operation.

2 December 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FCFrancesco Cabrucci
Francesco Cabrucci
Beatrice BacchiBeatrice Bacchi
Beatrice Bacchi
DPDario Petrone
Dario Petrone
Massimo BaudoMassimo Baudo
Massimo Baudo
Dimitrios E. MagouliotisDimitrios E. Magouliotis
Dimitrios E. Magouliotis
BRBasel Ramlawi
Basel Ramlawi
Objective: This study aimed to evaluate clinical and radiological outcomes of Ascyrus Medical Dissection Stent (AMDS®, Artivion Inc.) for acute type A aortic dissection (ATAAD). Methods: Between January 2021 and January 2025, all consecutive patients undergoing emergent surgery for ATAAD and hybrid aortic arch repair using the AMDS from two centers were retrospectively analyzed. Demographic, intraoperative, and postoperative data were collected. Patients were stratified based on 30-day or in-hospital mortality. Survival analysis was performed for patients who survived hospital discharge. Radiological evaluation focused on the presence of distal anastomotic new entries (DANEs), false lumen thrombosis, and aortic remodeling on follow-up computed tomography angiography. A total of 46 patients (12 female, mean age 66.1 ± 13.8 years) were included in the study. Results: The 30-day or in-hospital mortality rate was 21.7% (10 patients). There were no significant differences in demographic variables between survivors and non-survivors. All patients underwent hemiarch replacement with AMDS stent placement, with 54.3% also requiring aortic root replacement. Median cross-clamp time, hypothermic circulatory arrest (HCA) time, and time of antegrade selective cerebral perfusion did not differ significantly between the two groups. However, significant differences were observed in median cardiopulmonary bypass (CPB) time (151 vs. 274 min, p = 0.02) and HCA temperature (27 °C vs. 25 °C, p = 0.021). Postoperatively, the non-survivor group showed a significantly higher incidence of dialysis requirement (7.7% vs. 60.0%, p = 0.02), use of mechanical circulatory support (3.9% vs. 44.4%, p = 0.01), and re-exploration for bleeding (15.4% vs. 66.7%, p = 0.023). Conclusions: The AMDS® is an effective adjunct in hemiarch replacement for ATAAD. Moderate hypothermia and optimized perfusion were linked to better early survival, while the device reliably promoted true-lumen expansion with few DANEs. Its rapid deployment may further facilitate the use of moderate hypothermia by balancing procedural efficiency with systemic protection.

28 December 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Beatrice BacchiBeatrice Bacchi
Beatrice Bacchi
FCFrancesco Cabrucci
Francesco Cabrucci
BCBruno Chiarello
Bruno Chiarello
ADAleksander Dokollari
Aleksander Dokollari
Massimo BonacchiMassimo Bonacchi
Massimo Bonacchi
Background: Vasoplegic shock syndrome (VSS) after an off-pump coronary artery bypass graft (OPCABG) is an extremely rare condition. Inotropic support is usually the first-line therapy, though it can precipitate several complications or be ineffective. We report the first case of severe refractory VSS after OPCABG successfully treated with hydroxycobalamin. Methods: A 77-year-old gentleman underwent OPCABG for three vessels coronary artery disease. Preoperative LV ejection fraction was 28%, and the patient before surgery started sacubitril/valsartan titrated, then, at the highest dose. Surgery was uneventful and, by the end of the procedure, TEE showed improved biventricular contractility. Results: The patient was transferred to the ICU without inotropic support, but soon developed hypotension. TEE ruled out pericardial tamponade and confirmed fair contractility. Norepinephrine was titrated to a medium-high dose, vasopressin was started and a Swan-Ganz catheter was placed. SVR was 480 dyn·s·cm−5. Despite aggressive pharmacologic treatment (including methylprednisolone and methylene blue), no improvements were noticed. Ten grams of hydroxycobalamin were administered. One hour later, hemodynamic status re-assessment showed SVR > 800 dyn·s·cm−5. Afterward, vasopressors were gradually reduced. Conclusions: Our case demonstrated the importance of adequate early treatment in VSS after OPCABG. This case report shows, for the first time, that hydroxycobalamin was effectively used to restore homeostasis.